DE60118547D1 - Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält - Google Patents
Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthältInfo
- Publication number
- DE60118547D1 DE60118547D1 DE60118547T DE60118547T DE60118547D1 DE 60118547 D1 DE60118547 D1 DE 60118547D1 DE 60118547 T DE60118547 T DE 60118547T DE 60118547 T DE60118547 T DE 60118547T DE 60118547 D1 DE60118547 D1 DE 60118547D1
- Authority
- DE
- Germany
- Prior art keywords
- thalidomide
- treatment
- colorectal cancer
- irinotecane
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20414200P | 2000-05-15 | 2000-05-15 | |
US204142P | 2000-05-15 | ||
PCT/US2001/015326 WO2001087306A2 (en) | 2000-05-15 | 2001-05-10 | Compositions and methods for the treatment of colorectal cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60118547D1 true DE60118547D1 (de) | 2006-05-18 |
DE60118547T2 DE60118547T2 (de) | 2007-02-01 |
Family
ID=22756801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60118547T Expired - Lifetime DE60118547T2 (de) | 2000-05-15 | 2001-05-10 | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält |
Country Status (13)
Country | Link |
---|---|
US (2) | US6914067B2 (de) |
EP (1) | EP1286671B1 (de) |
JP (1) | JP4679028B2 (de) |
AT (1) | ATE322265T1 (de) |
AU (2) | AU6147301A (de) |
CA (1) | CA2408710C (de) |
DE (1) | DE60118547T2 (de) |
DK (1) | DK1286671T3 (de) |
ES (1) | ES2261415T3 (de) |
HK (1) | HK1053975A1 (de) |
NZ (1) | NZ522766A (de) |
PT (1) | PT1286671E (de) |
WO (1) | WO2001087306A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6881420B2 (en) * | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
AU2002328953A1 (en) * | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Use of irinotecan for improved treatment of cancer based on mdr1 |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
EP1900369A1 (de) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US6987012B2 (en) * | 2003-06-11 | 2006-01-17 | Ultra Biotech Limited | Biological compositions and methods for treatment of colorectal cancer |
EA200600921A1 (ru) * | 2003-11-06 | 2006-10-27 | Селджин Корпорейшн | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний |
PL1746976T3 (pl) | 2004-05-03 | 2017-09-29 | Merrimack Pharmaceuticals, Inc. | Liposomy przydatne w systemie podawania leków |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
US7994186B2 (en) * | 2005-04-18 | 2011-08-09 | Kabushiki Kaisha Yakult Honsha | Pharmaceutical compositions containing camptothecins |
BRPI0610351A2 (pt) * | 2005-05-19 | 2010-06-15 | Prometic Biosciences Inc | uso de compostos de triazina e medicamentos compreendendo os mesmos |
JP2009509171A (ja) * | 2005-09-21 | 2009-03-05 | シーシーシー ダイアグノスティックス, エルエルシー | 個別化抗癌化学療法(pac)のための包括的な診断試験 |
US20070219825A1 (en) * | 2005-11-23 | 2007-09-20 | Maetzold Derek J | Method of managing and reducing side effects associated with exposure to a drug |
US7723301B2 (en) * | 2007-08-29 | 2010-05-25 | The Board Of Trustees Of The University Of Arkansas | Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
RS64038B1 (sr) | 2014-08-22 | 2023-04-28 | Celgene Corp | Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima |
US10098813B2 (en) | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
SI3337467T1 (sl) | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
EP3791876A1 (de) | 2015-08-21 | 2021-03-17 | Ipsen Biopharm Ltd. | Verfahren zur behandlung von metastasierendem bauchspeicheldrüsenkrebs mithilfe von kombinationstherapien mt liposomalem irinotecan und oxaliplatin |
SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
MX2018009670A (es) | 2016-02-09 | 2019-09-04 | Sun Pharmaceutical Ind Ltd | Sistema de perfusion. |
SG11201903615WA (en) | 2016-11-02 | 2019-05-30 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
EP4017879A2 (de) * | 2019-08-19 | 2022-06-29 | Merus N.V. | Behandlung von krebs mit einer kombination eines antikörpers, der lgr5 und egfr bindet, und einem topoisomerase-i-hemmer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
EP1011675A1 (de) * | 1997-02-27 | 2000-06-28 | PHARMACIA & UPJOHN COMPANY | Tamoxifen-therapie um irinotecan-induzierte diarrhöe zu reduzieren |
-
2001
- 2001-05-10 AT AT01935372T patent/ATE322265T1/de active
- 2001-05-10 CA CA2408710A patent/CA2408710C/en not_active Expired - Fee Related
- 2001-05-10 EP EP01935372A patent/EP1286671B1/de not_active Expired - Lifetime
- 2001-05-10 WO PCT/US2001/015326 patent/WO2001087306A2/en active IP Right Grant
- 2001-05-10 DK DK01935372T patent/DK1286671T3/da active
- 2001-05-10 ES ES01935372T patent/ES2261415T3/es not_active Expired - Lifetime
- 2001-05-10 AU AU6147301A patent/AU6147301A/xx active Pending
- 2001-05-10 JP JP2001583774A patent/JP4679028B2/ja not_active Expired - Fee Related
- 2001-05-10 PT PT01935372T patent/PT1286671E/pt unknown
- 2001-05-10 AU AU2001261473A patent/AU2001261473B2/en not_active Ceased
- 2001-05-10 DE DE60118547T patent/DE60118547T2/de not_active Expired - Lifetime
- 2001-05-10 NZ NZ522766A patent/NZ522766A/en not_active IP Right Cessation
- 2001-05-14 US US09/853,619 patent/US6914067B2/en not_active Expired - Fee Related
-
2003
- 2003-08-23 HK HK03106060A patent/HK1053975A1/xx not_active IP Right Cessation
-
2005
- 2005-05-11 US US11/126,315 patent/US7479499B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050203060A1 (en) | 2005-09-15 |
DE60118547T2 (de) | 2007-02-01 |
ES2261415T3 (es) | 2006-11-16 |
AU6147301A (en) | 2001-11-26 |
JP2003533483A (ja) | 2003-11-11 |
WO2001087306A8 (en) | 2002-10-03 |
US7479499B2 (en) | 2009-01-20 |
EP1286671B1 (de) | 2006-04-05 |
PT1286671E (pt) | 2006-08-31 |
CA2408710A1 (en) | 2001-11-22 |
WO2001087306A2 (en) | 2001-11-22 |
AU2001261473B2 (en) | 2006-09-14 |
JP4679028B2 (ja) | 2011-04-27 |
ATE322265T1 (de) | 2006-04-15 |
EP1286671A2 (de) | 2003-03-05 |
DK1286671T3 (da) | 2006-07-17 |
NZ522766A (en) | 2005-09-30 |
US20020035091A1 (en) | 2002-03-21 |
HK1053975A1 (en) | 2003-11-14 |
CA2408710C (en) | 2010-01-26 |
US6914067B2 (en) | 2005-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60118547D1 (de) | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält | |
MXPA02011218A (es) | Composiciones y metodos para el tratamiento de cancer. | |
GEP20043375B (en) | APRIL-Receptor (BCMA) and Use Thereof | |
WO2004052280A3 (en) | Anti-angiogenic compounds and their use in cancer treatment | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
DE60023476D1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
IS6557A (is) | Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
WO2002040702A3 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
ATE344670T1 (de) | Synergistische kombination zur behandlung von kolorektalkarzinom | |
DE602006021348D1 (de) | Feste form von amg 706 und pharmazeutische zusammensetzungen davon | |
ATE359072T1 (de) | Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen | |
RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof | |
ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
DE69429856D1 (de) | Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit | |
ATE344664T1 (de) | Verbesserte methode zur eradikation von helicobacter pylori | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
ATE460168T1 (de) | Nicht-radioaktives strontiummittel zur behandlung von krebs | |
WO2007146375A3 (en) | Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer | |
ATE407925T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
ATE468130T1 (de) | Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie | |
DE60137506D1 (de) | Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose | |
ATE402147T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |